Quick Answer
Structure Therapeutics Inc. reported Stockholders Equity of $1.52 billion for the year ending 2025.
- Structure Therapeutics Inc. showed an increase of +75.3% in Stockholders Equity from 2024 to 2025.
- This data is from Structure Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: -$77.23 million | Q2 2022: -$92.10 million | Q3 2022: -$103.91 million | Q1 2023: $236.35 million | Q2 2023: $214.42 million | Q3 2023: $192.96 million | Q1 2024: $429.82 million | Q2 2024: $921.03 million | Q3 2024: $896.80 million | Q1 2025: $824.64 million | Q2 2025: $772.08 million | Q3 2025: $770.02 million.
- Over the full 5 years of available data (2021 to 2025), Structure Therapeutics Inc.'s Stockholders Equity has grown by 2,442.4%.
- Historical annual values: Fiscal year 2025: $1.52 billion | Fiscal year 2024: $864.84 million | Fiscal year 2023: $452.97 million | Fiscal year 2022: -$115.14 million | Fiscal year 2021: -$64.74 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: